Green MD - Search Results

1

Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia.

Rosenthal MA, Rischin D, McArthur G, Ribbons K, Chong B, Fareed J, Toner G, Green MD, Basser RL. Rosenthal MA, et al. Among authors: green md. Ann Oncol. 2002 May;13(5):770-6. doi: 10.1093/annonc/mdf117. Ann Oncol. 2002. PMID: 12075747 Free article. Clinical Trial.

2

Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.

Basser RL, Sobol MM, Duggan G, Cebon J, Rosenthal MA, Mihaly G, Green MD. Basser RL, et al. Among authors: green md. J Clin Oncol. 1994 Aug;12(8):1659-66. doi: 10.1200/JCO.1994.12.8.1659. J Clin Oncol. 1994. PMID: 8040678 Clinical Trial.

3

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer.

Basser RL, Abraham R, To LB, Fox RM, Green MD. Basser RL, et al. Among authors: green md. Ann Oncol. 1999 Jan;10(1):53-8. doi: 10.1023/a:1008390203340. Ann Oncol. 1999. PMID: 10076722 Free article. Clinical Trial.

4

Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors.

Talbot SM, Westerman DA, Grigg AP, Toner GC, Wolf M, Bishop J, McKendrick J, Zalcberg J, Levi J, Fox RM, Green MD. Talbot SM, et al. Among authors: green md. Ann Oncol. 1999 Aug;10(8):907-14. doi: 10.1023/a:1008353522601. Ann Oncol. 1999. PMID: 10509151 Free article. Clinical Trial.

5

Phase I and pharmacokinetic study of photodynamic therapy for high-grade gliomas using a novel boronated porphyrin.

Rosenthal MA, Kavar B, Hill JS, Morgan DJ, Nation RL, Stylli SS, Basser RL, Uren S, Geldard H, Green MD, Kahl SB, Kaye AH. Rosenthal MA, et al. Among authors: green md. J Clin Oncol. 2001 Jan 15;19(2):519-24. doi: 10.1200/JCO.2001.19.2.519. J Clin Oncol. 2001. PMID: 11208846 Clinical Trial.

6

Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.

Green MD, Francis PA, Gebski V, Harvey V, Karapetis C, Chan A, Snyder R, Fong A, Basser R, Forbes JF; Australian New Zealand Breast Cancer Trials Group. Green MD, et al. Ann Oncol. 2009 Nov;20(11):1813-7. doi: 10.1093/annonc/mdp202. Epub 2009 Jun 24. Ann Oncol. 2009. PMID: 19553291 Free article. Clinical Trial.

7

Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancer.

Basser RL, Green MD, Sheridan WP, Fox RM. Basser RL, et al. Among authors: green md. Cancer Chemother Pharmacol. 1992;30(2):161-3. doi: 10.1007/BF00686412. Cancer Chemother Pharmacol. 1992. PMID: 1600598 Clinical Trial.

8

Recent advances in carcinoids and gastrointestinal neuroendocrine tumors.

Basser RL, Green MD. Basser RL, et al. Among authors: green md. Curr Opin Oncol. 1991 Feb;3(1):109-20. doi: 10.1097/00001622-199102000-00016. Curr Opin Oncol. 1991. PMID: 2043691 Review.

9

Strategies for prevention of anthracycline cardiotoxicity.

Basser RL, Green MD. Basser RL, et al. Among authors: green md. Cancer Treat Rev. 1993 Jan;19(1):57-77. doi: 10.1016/0305-7372(93)90027-o. Cancer Treat Rev. 1993. PMID: 8431927 Review. No abstract available.

10

Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.

Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Hussein S, Alt C, Menchaca D, Tomita D, Marty J, Fox RM, Begley CG. Basser RL, et al. Among authors: green md. Lancet. 1996 Nov 9;348(9037):1279-81. doi: 10.1016/S0140-6736(96)04471-6. Lancet. 1996. PMID: 8909381 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

404 results

Search Page

Filters